Xenon Pharmaceuticals (XENE) & Its Competitors Financial Analysis
Xenon Pharmaceuticals (NASDAQ: XENE) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Xenon Pharmaceuticals to related businesses based on the strength of its institutional ownership, earnings, profitability, risk, valuation, analyst recommendations and dividends.
Volatility and Risk
Xenon Pharmaceuticals has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals’ peers have a beta of 6.66, indicating that their average stock price is 566% more volatile than the S&P 500.
This table compares Xenon Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Xenon Pharmaceuticals Competitors||-5,511.49%||-449.46%||-42.33%|
Insider & Institutional Ownership
55.3% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.5% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 9.4% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Xenon Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Xenon Pharmaceuticals||$819,999.00||-$28.01 million||-1.77|
|Xenon Pharmaceuticals Competitors||$260.16 million||$66.28 million||-6.61|
Xenon Pharmaceuticals’ peers have higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current recommendations for Xenon Pharmaceuticals and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Xenon Pharmaceuticals Competitors||764||3033||11183||227||2.71|
Xenon Pharmaceuticals presently has a consensus price target of $8.17, suggesting a potential upside of 176.84%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 37.56%. Given Xenon Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Xenon Pharmaceuticals is more favorable than its peers.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.